The impact of earlier intervention by an antimicrobial stewardship team for specific antimicrobials in a single weekly intervention

Int J Infect Dis. 2018 Dec:77:34-39. doi: 10.1016/j.ijid.2018.09.025. Epub 2018 Oct 4.

Abstract

Objective: The objective of this study was to evaluate the effects of earlier intervention by an antimicrobial stewardship team (AST) on antimicrobial use, antimicrobial resistance rates, and the clinical outcomes, without changing the weekly intervention schedule.

Methods: A retrospective study was conducted at Fukuoka University Hospital between April 2013 and March 2016. The effects were compared among three study periods (SP): SP1 (patients receiving anti-methicillin-resistant Staphylococcus aureus agents and carbapenems for ≥14 days), SP2 (patients receiving specific antimicrobials for ≥14 days), and SP3 (patients receiving specific antimicrobials regardless of the duration of treatment).

Results: The timing of AST intervention was shortened from an average of 15.5days after administration in SP1 to 4.2 days in SP3. The antimicrobial use density (AUD) of carbapenems and piperacillin-tazobactam decreased significantly (SP2 vs. SP3, p<0.05), and the costs of specific antimicrobials decreased (SP1, US$ 1080000; SP2, US$ 944000; SP3, US$ 763000). The rates of carbapenem resistance among Pseudomonas aeruginosa isolates showed a significant reduction from 16.2% in SP2 to 8.7% in SP3 (p<0.05). The mortality rate and length of stay did not change during the study period.

Conclusions: Earlier intervention by an AST could contribute to the proper use of antimicrobials without adversely affecting patient outcomes.

Keywords: Antimicrobial resistance; Antimicrobial stewardship program; Antimicrobial use density; Cost; Pseudomonas aeruginosa.

MeSH terms

  • Anti-Infective Agents / economics
  • Anti-Infective Agents / therapeutic use*
  • Antimicrobial Stewardship*
  • Carbapenems / economics
  • Carbapenems / therapeutic use
  • Daptomycin / therapeutic use
  • Drug Resistance, Microbial
  • Fluoroquinolones / therapeutic use
  • Humans
  • Linezolid / therapeutic use
  • Methicillin-Resistant Staphylococcus aureus / drug effects
  • Piperacillin, Tazobactam Drug Combination / economics
  • Piperacillin, Tazobactam Drug Combination / therapeutic use
  • Pseudomonas aeruginosa / drug effects
  • Retrospective Studies
  • Teicoplanin / therapeutic use
  • Time Factors
  • Treatment Outcome
  • Vancomycin / therapeutic use

Substances

  • Anti-Infective Agents
  • Carbapenems
  • Fluoroquinolones
  • Piperacillin, Tazobactam Drug Combination
  • Teicoplanin
  • Vancomycin
  • Linezolid
  • Daptomycin